PT - JOURNAL ARTICLE AU - NORIO NAKAMURA AU - RYUICHIRO KUMASAKA AU - HIROSHI OSAWA AU - HIDEAKI YAMABE AU - KEN-ICHI SHIRATO AU - TAKESHI FUJITA AU - REI-ICHI MURAKAMI AU - MICHIKO SHIMADA AU - MASAYUKI NAKAMURA AU - KEN OKUMURA AU - KEI HAMAZAKI AU - TOMOHITO HAMAZAKI TI - Effects of Eicosapentaenoic Acids on Oxidative Stress and Plasma Fatty Acid Composition in Patients with Lupus Nephritis DP - 2005 Sep 01 TA - In Vivo PG - 879--882 VI - 19 IP - 5 4099 - http://iv.iiarjournals.org/content/19/5/879.short 4100 - http://iv.iiarjournals.org/content/19/5/879.full SO - In Vivo2005 Sep 01; 19 AB - Eicosapentaenoic acid (EPA) is one of the major components of fish oil, which was reported to have anti-atherogenic, anti-inflammatory and immune suppressive effects. In the present study, highly purified EPA was administered to patients with lupus nephritis and the effects of EPA on urinary 8-isoprostane, a reliable marker of oxidative stress, were investigated in these patients. Six outpatients (1 man and 5 women), with lupus nephritis diagnosed by renal biopsy, were entered in the study. We administered 1800 mg EPA ethyl-ester (purity >95%) daily and examined the urinary 8-isoprostane levels and plasma fatty acid composition before and 3 months after EPA treatment. The urinary 8-isoprostane levels were significantly decreased after the treatment compared with those before the treatment (from 530±113 pg/mg · Cr to 235±49 pg/mg · Cr, p=0.02). The EPA levels in the plasma phospholipid (PL) fraction were significantly increased after the treatment (from 3.30±0.64 mol% to 8.01±0.47 mol%, p<0.001). Arachidonic acid (AA) levels in the plasma PL fraction were significantly decreased after the treatment (from 9.47±0.28 mol% to 7.33±0.43 mol%, p<0.001). The ratios of EPA to AA were significantly increased after the treatment (from 0.35±0.07 to 1.14±0.16, p<0.001). Thus, this preliminary study indicated that EPA might exert beneficial effects on lupus nephritis by decreasing the oxidative stress. Copyright © 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved